Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
January 17 2023 - 7:10AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company that has developed
two commercially available oral immunotherapeutic products for the
treatment of gut mediated diseases, is pleased to announce that has
been granted a European Patent for compositions and methods for the
treatment and/or prophylaxis of Clostridioides difficile associated
disease.
Notification of the decision to grant European
Patent 14784945.9, entitled “Methods and Compositions for the
treatment and/or prophylaxis of Clostridium difficile associated
disease,” was formally received yesterday, and grant of this
application will be published in the European Patent Bulletin on 25
January 2023 under European Patent No. 2986316. The company
previously reported it had received notification from the European
Patent Office of the intent to grant in July last year (ASX
announcement July 7, 2022).
The European registration adds to Immuron's
patent position for compositions and methods for the treatment
and/or prophylaxis of Clostridioides difficile associated disease
in Australia, New Zealand and the United States.
Clostridioides difficile (previously known as
Clostridium difficile) infection (CDI) is a disease of the large
intestine caused by toxins produced by the spore forming bacterium
Clostridioides difficile. CDI can also result in serious disease
complications including bowel perforation, toxic megacolon and
sepsis, and it can prove fatal in the most severe cases. In recent
years, increases in the frequency and severity of CDI have been
observed worldwide, as well as an increased risk of
community-associated CDI, and CDI in persons previously thought to
be low risk. It is estimated that CDI affects up to 1.2% of
hospitalized patients in the United States, representing an
estimated cost of USD 4.8 billion per year (source: CDC). In
Europe, the estimated cost is approximately 3 billion per year,
which is likely to increase concomitantly with a more elderly
society; more than 134 million Europeans will be >65 years by
2050.
This release has been authorised by the
directors of Immuron Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious
diseases.
About IMM-529IMM-529 is a
polyclonal antibody biological product intended to prevent and
treat Clostridioides difficile (C.difficile) infections and has
been developed to spare the gut microbiome from the effects of
"classic" antibiotic treatments. The delivery of IMM-529 results in
localized toxin B neutralization at the site of infection and
prevents severe damage occurring to the gut while also binding to
C.difficile spores and vegetative cells preventing further
colonization. In addition, the antibodies in IMM-529 have
demonstrated cross-reactions with a variety of human and animal
C.difficile isolates and their associated Toxin B, vegetative cell
and spore components. The antibodies in IMM-529 have also been
shown to neutralize Toxin B from a historical C. difficile strain
(630) and from a hypervirulent (HV) strain which caused a worldwide
outbreak of the disease.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Jul 2023 to Jul 2024